A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)

Exclusion Criteria

• •Pre-menopausal women who have no birth control, who are pregnant or nursing
• •Patients with advanced hepatic impairment or advanced renal impairment
• •Patients with New York Heart Association (NYHA) functional class III or IV congestive heart failure (CHF), unstable angina, acute myocardial infarction, heart surgery or stroke within the previous six months
• •Patients with any type of relevant arrhythmia according to the assessment of the investigator
• •Patients with any valvular disease with hemodynamic repercussion
• •Patients receiving chronic administration of oral anticoagulants or digoxin
• •Patients with known hypersensitivity to any component in the formulation of Micardis®, Telmisartan or Micardis Plus®, Telmisartan hydrochlorothiazide
• •Patients with previous history of angioedema associated with angiotensin converting enzyme (ACE) inhibitors
• •Patients with severe, uncontrolled hypertension or any form of secondary hypertension
• •Patients with any other clinical conditions which, in the opinion of the investigator, would not allow for the safe completion of the protocol